- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Active Pharmaceutical Ingredients Market to touch US$119.7 Billion by 2020: Transparency Market Research
According to the latest Transparency Market Research report the global active pharmaceuticals ingredients (APIs) market stood at US$119.7 bn in 2014 and is predicted to reach US$185.9 bn by 2020.
According to the latest Transparency Market Research report the global active pharmaceuticals ingredients (APIs) market stood at US$119.7 bn in 2014 and is predicted to reach US$185.9 bn by 2020.
According to the research:
It is expected to expand at a CAGR of 6.50% from 2014 to 2020. The title of the report is “Active Pharmaceutical Ingredients (API) Market: (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”.
The global pharmaceutical industry has suffered enormously due to patent expiry of blockbuster drugs in the past few years. However, this has facilitated a surge in the demand for low-cost substitutes across the globe resulting in a boost to active pharmaceutical ingredient (API) manufacturing. The approvals of biosimilars in Europe has added to the total API market revenue, and the recent approval of Novartis’ filgrastim biosimilar in the U.S. is expected to continue the upward trend in this market. The overall global active pharmaceutical ingredients market was valued at USD 119.7 billion in 2013 and is anticipated to reach USD 185.9 billion by 2020, expanding at a CAGR of 6.5% during the forecast period from 2014 to 2020.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.